表紙
市場調查報告書

C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4):開發平台分析

C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 361648
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4):開發平台分析 C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 60 Pages
簡介

本報告提供全球各國的C-C趨化素受體類型4 (C-CCKR-4或K5-5或CD194或CCR4)的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊 ,為您概述為以下內容。

目錄

簡介

  • 分析範圍

C-C趨化素受體類型4 (C-C CKR-4/K5-5/CD194/CCR4)的概要

治療藥的開發情形

  • 臨床實驗的各階段
  • 各治療領域
  • 各症狀

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

各企業開發中的治療藥

治療藥的評估

  • 單劑治療藥/並用治療藥的情況
  • 各作用機制
  • 各投藥法
  • 各分子類型

開發治療藥的企業

  • AstraZeneca Plc
  • ChemoCentryx, Inc.
  • Globavir Biosciences, Inc.
  • Kyowa Hakko Kirin
  • 小野藥品工業

藥物簡介

  • ZD-2098
    • 產品概要
    • 作用機制
    • 研究開發 (R&D)的發展情形
  • CCX-6239
  • E-0001163
  • GBV-3019
  • K-777
  • Mogamulizumab
  • 腫瘤、自體免疫疾病用CCR、CXCR拮抗用小分子

開發暫停的產品

開發中止的產品

值得注意的最新趨勢、新聞稿 (共15件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2090TDB

Summary

According to the recently published report 'C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019'; C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.

The report 'C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019' outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Ophthalmology and Respiratory which include indications Gastric Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, T-Cell Lymphomas, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Allergic Asthma, Allergic Conjunctivitis, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Cervical Cancer, Chronic Urticaria Or Hives, Colon Tumor, Colorectal Cancer, Eosinophilic Esophagitis, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Hepatocellular Carcinoma (HCC), Mycosis Fungoides, Nasopharyngeal Cancer, Oral Cancer, Ovarian Cancer, Pancreatic Tumor, Rhinosinusitis, Sezary Syndrome, Solid Tumor, Spinal Cord Disorders, T-Cell Leukemia, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Tropical Spastic Paraparesis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
  • Affitech A/S
  • ChemoCentryx Inc
  • Kyowa Kirin Co Ltd
  • RAPT Therapeutics Inc
  • Tizona Therapeutics Inc
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
  • AT-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CCX-6239 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FLX-475 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mogamulizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RPT-193 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
  • Jul 08, 2019: RAPT Therapeutics announces the appointment of Emma Guttman-Yassky, M.D., Ph.D., a leading expert in the field of inflammatory skin diseases, to its scientific advisory board
  • Jun 03, 2019: Kyowa Kirin presents post-hoc analysis of pivotal trial for Poteligeo (mogamulizumab-kpkc)
  • May 13, 2019: FLX Bio highlights preclinical atopic dermatitis and asthma data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
  • Dec 03, 2018: Kyowa Kirin presents additional analyses of MAVORIC trial
  • Nov 29, 2018: ChemoCentryx announces presentation on novel small molecule inhibitor CCX6239 at American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
  • Nov 26, 2018: Kyowa Kirin announces POTELIGEO receives Marketing Authorisation in Europe for the treatment of Mycosis Fungoides and Sezary Syndrome
  • Nov 08, 2018: FLX Bio highlights phase 1 data for FLX475 at SITC 2018
  • Sep 28, 2018: Kyowa Kirin presents data at EORTC-Cutaneous Lymphoma Task Force Meeting showing significantly improved quality of life for patients With Mycosis Fungoides (MF) and Sezary Syndrome (SS) on Mogamulizumab
  • Sep 27, 2018: FLX Bio announces first patient dosed with FLX475, a best-in-class CCR4 inhibitor for the treatment of multiple cancers
  • Sep 21, 2018: Kyowa Kirin announces Mogamulizumab received positive CHMP opinion for the treatment of Mycosis Fungoides and Sezary Syndrome
  • Aug 29, 2018: New therapy for rare lymphoma
  • Aug 21, 2018: Kyowa Hakko Kirin receives the partial change approval of POTELIGEO in Japan
  • Aug 13, 2018: Kyowa Kirin reports positive results from MAVORIC study
  • Aug 10, 2018: FDA approves Kyowa Kirin's Poteligeo to treat two lymphoma types
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Affitech A/S, H2 2019
  • Pipeline by ChemoCentryx Inc, H2 2019
  • Pipeline by Kyowa Kirin Co Ltd, H2 2019
  • Pipeline by RAPT Therapeutics Inc, H2 2019
  • Pipeline by Tizona Therapeutics Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top